1. Introduction {#sec1-plants-09-00842}
===============

Recombinant proteins are complex exogenous ("foreign") proteins that are produced in expression hosts, and mainly used as medical diagnostic reagents and in human healthcare as vaccines, drugs, or monoclonal antibodies \[[@B1-plants-09-00842]\]. The prominent role and increasing market demand for high-value recombinant proteins in novel drug discovery creates an opportunity for the development of various protein expression hosts to manufacture proteins by following the existing rigid standards laid down for veterinary and human applications. The industry is focusing mainly on already established production platforms using prokaryotic and eukaryotic expression host systems such as *Escherichia coli*, a selection of yeast, insect, and mammalian cell cultures, due to their well-defined processes in-line with current good manufacturing practice (cGMP) \[[@B2-plants-09-00842]\]. Moreover, industrially established mammalian and other cell cultures have stringent regulatory approval in place, which hinders the industrial acceptance of the new technology or production system. Bacterial expression systems offer rapid production with high product yield, whereas *Saccharomyces cerevisiae* and *Pichia pastoris* (yeast) offer post-translational modifications (PTMs) which are essential for functional activity of the recombinant proteins \[[@B3-plants-09-00842]\]. The majority of the approved recombinant biopharmaceuticals are produced in mammalian cell lines \[[@B4-plants-09-00842]\]. However, all the production systems have their own merits and setbacks such as production time, high operating costs, protein yield, chances of contamination with pathogenic microorganisms, limited post-translational modifications, and regulatory approval. In order to compete with the established platform, the new expression system must have unique advantages that can overcome the limitations of the existing ones. Plants offer several potential benefits over conventional expression platforms and prove the reliability of the system for the production of highly valuable proteins. Advancements in plant molecular farming approaches in the recent decade have made plants an attractive manufacturing system that can even achieve commercially relevant production levels in a short period \[[@B1-plants-09-00842],[@B5-plants-09-00842],[@B6-plants-09-00842]\]. As the progress is continuously being made in this ever-growing field, here in this review, we summarize the importance and prospects of plant expression systems for the cost-effective production of recombinant proteins. Potential vaccine candidates, monoclonal antibodies, and industrial enzymes expressed in plants are also described.

2. Plant Expression Platform {#sec2-plants-09-00842}
============================

Plants were utilized for the expression of recombinant proteins from the late 1980s \[[@B7-plants-09-00842]\]. Since then, the plant expression platform has faced several hurdles, until recently the first plant-based product "Elelyso" was commercialized by Protalix Biotherapeutics for the treatment of Gaucher's disease in 2012 \[[@B8-plants-09-00842]\]. The practice of using plants for high-value recombinant protein production ranging from pharmaceutical therapeutics to non-pharmaceutical products such as antibodies, vaccine antigens, enzymes, growth factors, research or diagnostic reagents, and cosmetic ingredients \[[@B9-plants-09-00842]\] has improved over time and advanced significantly in recent decades, which in turn has led to a major paradigm shift in the pharmaceutical sector. The technology has rapidly developed, and the potential drawbacks associated with plant molecular farming during their early stages of development, including the need for a high protein expression level and efficient downstream processing, have now been achieved. The advantages of plant expression platforms are cited in several earlier reports showing head-to-head comparisons with other existing platforms ([Table 1](#plants-09-00842-t001){ref-type="table"}) \[[@B10-plants-09-00842],[@B11-plants-09-00842],[@B12-plants-09-00842],[@B13-plants-09-00842],[@B14-plants-09-00842],[@B15-plants-09-00842],[@B16-plants-09-00842],[@B17-plants-09-00842],[@B18-plants-09-00842]\]. The key advantages of all plant-based systems are easy cultivation, low expenses, low or no pathogen load, rapid mass production of recombinant proteins, and the ability of the plants to assemble complex proteins with eukaryotic-like post-translational modifications (PTMs) \[[@B19-plants-09-00842]\].

Protein folding is highly essential to retain the biological activity of the recombinant therapeutic proteins. Due to the lack of the protein processing complex and limited capacity for PTMs, proper protein folding cannot be achieved in the prokaryotic expression system \[[@B20-plants-09-00842]\]. Plants have the capacity to assemble and perform PTMs of large multimeric proteins required for their functional biological activity. However, plants lack the authentic human *N*-glycosylation processing mechanism which has been overcome by the glycoengineering approaches towards the synthesis of targeted human and non-human structures to increase product homogeneity, quality, and quantity \[[@B21-plants-09-00842],[@B22-plants-09-00842]\].

The *Nicotiana* genus is often used for genetic transformation studies due to its growth rate and easy genetic manipulation. Most of the recombinant proteins such as pharmaceuticals, vaccines, hormones, cytokines, growth regulators, and industrial products are produced in tobacco, which is considered as a molecular biology workhouse of the plant world. *Nicotiana benthamiana* and *N. tabacum* are two common species used for the stable and transient expression of recombinant proteins. Further, several cereal crops, fruits, and vegetables such as rice, maize, lettuce, tomato, potato, and alfalfa were also evaluated for their applicability in plant molecular farming (PMF) depending on the protein target and application \[[@B1-plants-09-00842]\]. Many plant-produced therapeutic proteins are in pre-clinical and clinical trials and are close to commercialization \[[@B23-plants-09-00842],[@B24-plants-09-00842]\]. The strength and bottlenecks of the commercial potential of the plant expression system was critically reviewed and summarized by Schillberg et al. (2019) \[[@B2-plants-09-00842]\].

plants-09-00842-t001_Table 1

###### 

Available expression platforms for recombinant protein production with potential advantages and disadvantages (adapted from Shanmugaraj et al., 2020) \[[@B25-plants-09-00842]\].

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Expression System   Advantages                                                                                      Disadvantages
  ------------------- ----------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
  Bacteria            Easy to manipulate\                                                                             Improper folding\
                      Low cost\                                                                                       Lack of post-translational modifications which may affect the protein function\
                      High expression\                                                                                Endotoxin accumulation
                      Ease of scale up\                                                                               
                      Short turnaround time\                                                                          
                      Established regulatory procedures and approval                                                  

  Mammalian Cells     Proper folding and authentic post-translational modifications\                                  High production cost\
                      Existing regulatory approval                                                                    Expensive media and culture condition requirements

  Yeast               Rapid growth and scalable\                                                                      Difficulty in cell disruption due to the thick and hard cell walls\
                      Easy to manipulate\                                                                             Hyperglycosylation of proteins\
                      Simple and inexpensive media requirements and culture conditions\                               Limited glycosylation capacity
                      Post-translational modifications of recombinant proteins                                        

  Insect cells        High expression levels\                                                                         High cost and time consuming\
                      Ability to produce complex proteins including secreted, membrane, and intracellular proteins\   Expensive media and culture condition requirements
                      Proper folding and post-translational modifications                                             

  Plant               Rapid and affordable\                                                                           Regulatory compliance\
                      Optimized growth conditions\                                                                    Limited glycosylation capacity
                      Free from pathogen and bacterial toxin contaminants\                                            
                      Economical\                                                                                     
                      Post-translational modification somewhat similar like mammalian system                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

3. Plant-Derived Recombinant Proteins {#sec3-plants-09-00842}
=====================================

The concept of using plants for the production of foreign proteins including pharmaceutical and non-pharmaceutical proteins has been well explored and documented. Many reports proved the ability of in vivo and in vitro plant systems to produce vaccine candidates both for veterinary and human applications and showed that plant-produced antigens elicit potential immune responses in animal models and even confer protection in animal challenge experiments. Examples of the variety of pharmaceutical and non-pharmaceutical proteins expressed in plant systems are illustrated in [Table 2](#plants-09-00842-t002){ref-type="table"} and [Table 3](#plants-09-00842-t003){ref-type="table"}.

Tobacco has been engineered to express a variety of antigens in the nucleus and chloroplast including, but not limited to, chikungunya, dengue, Ebola, influenza, and Zika. The transformation protocols for recombinant protein production are also established for fruits and vegetables such as tomatoes and potatoes. Transgenic potatoes expressing the S1 glycoprotein of the infectious bronchitis virus confers protection to chickens upon virus challenge \[[@B26-plants-09-00842]\]. Leafy crops such as lettuce, alfalfa, and clover have been investigated for molecular farming to obtain the oral delivery of vaccine antigens eliminating purification and injections. The lettuce chloroplast-derived booster vaccine using lyophilized plant cells expressing the poliovirus capsid protein induced neutralization antibodies in mice primed with inactivated poliovirus vaccine (IPV) and conferred protection against all polio serotypes \[[@B27-plants-09-00842]\]. Plant systems have also been evaluated for the expression of virus-like particles (VLP) of many viruses including norovirus, poliovirus, foot-and-mouth disease virus, influenza, \[[@B28-plants-09-00842],[@B29-plants-09-00842],[@B30-plants-09-00842],[@B31-plants-09-00842]\], and the potential for plant-derived VLPs to be used as candidate vaccines and reagents has been reviewed in detail elsewhere \[[@B18-plants-09-00842],[@B32-plants-09-00842],[@B33-plants-09-00842]\]. Apart from expressing antigens for human diseases, several antigens for veterinary applications and non-pharmaceutical proteins have also been well tested for expression in plants, and are particularly gaining attention due to the fact that these products can quickly reach the market due to lower regulatory burden \[[@B9-plants-09-00842]\]. This was clearly evidenced by the commercialization of avidin \[[@B34-plants-09-00842]\], *β*-glucuronidase \[[@B35-plants-09-00842]\], and trypsin \[[@B36-plants-09-00842]\] by the US-based biotechnology company ProdiGene, Inc. The vaccine against Newcastle disease virus (NDV) was the first plant-based poultry vaccine (Dow Agrosciences) that obtained regulatory approval from the United States Department of Agriculture in 2006, opening a new avenue for the commercialization of plant-derived vaccines. Currently, many plant-derived non-pharmaceutical and pharmaceutical proteins are in clinical development.

Although proof-of-concept and efficacy of many vaccine candidates proved the feasibility and scalability of the robust plant system, it is high time to compete with the established expression systems. Now the plant-based good manufacturing practices (GMP) complaint production facilities such as Fraunhofer (Germany), Kentucky BioProcessing (USA), Medicago (Canada), and Protalix Biotherapeutics (Israel) are available to manufacture GMP materials for human clinical trials. Fraunhofer IME received a GMP license for the production of neutralizing anti-HIV antibody 2G12 in tobacco for phase I clinical testing \[[@B37-plants-09-00842]\]. The plant molecular farming research community continuously thrives to set up a regulatory framework for plant-derived products.

plants-09-00842-t002_Table 2

###### 

Selected list of vaccine candidates and antibodies expressed in plants against various diseases.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Vaccine Candidates                                                                                                                                                                                                                                                            
  -------------------------------------------------------------- --------------------------------------------------------------- --------------------------------------- ------------------------------------------------------ ----------------------------------------------- ----------------------------
  Hepatitis B surface antigen                                    Hepatitis B virus                                               Tobacco (*Nicotiana tabacum*)           *Agrobacterium* mediated\                              66 ng/mg of soluble protein                     \[[@B38-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Structural protein VP60                                        Rabbit hemorrhagic disease virus (RHDV)                         Potato (*Solanum tuberosum*)            *Agrobacterium* mediated\                              0.3% of total soluble protein                   \[[@B39-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Spike (S) protein of transmissible gastroenteritis virus       Transmissible gastroenteritis virus (TGEV)                      Tobacco (*Nicotiana tabacum*)           *Agrobacterium* mediated\                              0.1--0.2% of total soluble protein              \[[@B40-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Hemagglutinin protein of rinderpest virus                      Rinderpest virus (RPV)                                          Peanut (*Arachis hypogea* L.)           *Agrobacterium* mediated\                              0.2--1.3% of total soluble protein              \[[@B41-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Glycoprotein D (gD) of bovine herpes virus                     Bovine herpes virus                                             Tobacco (*Nicotiana benthamiana*)       Mechanical inoculation (Stable expression/Nucleus)     20 μg/g fresh weight (FW)                       \[[@B42-plants-09-00842]\]

  L1 major capsid protein                                        Human papillomavirus                                            Tobacco (*Nicotiana tabacum*)           *Agrobacterium* mediated\                              2--4 µg/kg FW                                   \[[@B43-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Spike (S) protein of transmissible gastroenteritis virus       Transmissible gastroenteritis virus (TGEV)                      Corn (*Zea mays*)                       *Agrobacterium* mediated\                              13 mg/kg FW                                     \[[@B44-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Spike (S) protein of infectious bronchitis virus               Infectious bronchitis virus (IBV)                               Potato *(Solanum tuberosum)*            *Agrobacterium* mediated\                              2.39--2.53 µg/g FW                              \[[@B26-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Anthrax protective antigen (PA)                                Anthrax                                                         Tobacco (*Nicotiana tabacum*)           Biolistic method (Stable expression/Chloroplast)       14.2% of total soluble protein                  \[[@B45-plants-09-00842]\]

  Hepatitis B virus surface antigen                              Hepatitis B virus (HBV)                                         Potato (*Solanum tuberosum*)            *Agrobacterium* mediated\                              8.5 μg/g FW                                     \[[@B46-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Fusion (F) protein of Newcastle disease virus                  Newcastle disease virus (NDV)                                   Corn (*Zea mays* L.)                    Biolistic method (Stable expression/Chloroplast)       3.0% of total soluble protein                   \[[@B47-plants-09-00842]\]

  F4 fimbrial adhesin FaeG                                       Enterotoxigenic *E. coli*                                       Alfalfa (*Medicago sativa* L.)          *Agrobacterium* mediated\                              1.0% of total soluble protein                   \[[@B48-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Chloroplast)                                                                        

  L1 capsid protein gene                                         Cottontail rabbit papillomavirus                                Tobacco (*Nicotiana tabacum*)           *Agrobacterium* mediated\                              0.4--1 mg/kg of total leaf mass                 \[[@B49-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Structural protein VP2                                         Infectious bursal disease virus (IBDV)                          Rice                                    *Agrobacterium* mediated\                              40.21 µg/g FW                                   \[[@B50-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Hepatitis B virus surface antigen                              Hepatitis B virus (HBV)                                         Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated\                              295 µg/g FW                                     \[[@B51-plants-09-00842]\]
                                                                                                                                                                         (Transient expression)                                                                                 

  Haemagglutinin (HA)                                            H5N1 (avian influenza virus) & H1N1 (human) influenza strains   Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated\                              50 mg/kg FW                                     \[[@B52-plants-09-00842]\]
                                                                                                                                                                         (Transient expression)                                                                                 

  Heat-labile toxin B subunit (LTB)                              Enterotoxigenic *E. coli*                                       Carrot\                                 *Agrobacterium* mediated\                              0.3% of total soluble protein                   \[[@B53-plants-09-00842]\]
                                                                                                                                 (*Daucus carota*)                       (Stable expression/Nucleus)                                                                            

  Norwalk virus capsid protein                                   Norwalk virus                                                   Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated\                              0.8 mg/g FW                                     \[[@B54-plants-09-00842]\]
                                                                                                                                                                         (Transient expression)                                                                                 

  Structural protein VP1                                         Foot-and-mouth disease virus (FMDV)                             Legume (*Stylosanthes guianensis*)      *Agrobacterium* mediated\                              0.1--0.5% of total soluble protein              \[[@B55-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  HIV-1 Pr55gag Polyprotein                                      Human immunodeficiency virus type 1 (HIV)                       Tobacco (*Nicotiana tabacum*)           Biolistic method (Stable expression/Chloroplast)       312--363 mg/kg FW                               \[[@B56-plants-09-00842]\]

  Japanese encephalitis virus (JEV) envelope protein (E)         Japanese encephalitis virus                                     Japonica rice (*Nipponbare*)            *Agrobacterium* mediated\                              1.1--1.9 μg/mg of total soluble protein         \[[@B57-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Hemagglutinin (HA)                                             Avian influenza (H5N1)                                          Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated\                              0.3 g/kg FW                                     \[[@B58-plants-09-00842]\]
                                                                                                                                                                         (Transient expression)                                                                                 

  Haemagglutinin (HA)                                            Influenza virus                                                 Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        400--1300 mg/kg FW                              \[[@B59-plants-09-00842]\]

  Haemagglutinin (HA)                                            Avian influenza A (H7N7)                                        Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        0.2 g/kg FW                                     \[[@B60-plants-09-00842]\]

  Structural protein VP2                                         Infectious bursal disease virus (IBDV)                          Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated\                              1.0% of total soluble protein                   \[[@B61-plants-09-00842]\]
                                                                                                                                                                         (Transient expression)                                                                                 

  Structural protein E2                                          Bovine viral diarrhea virus (BVDV)                              Alfalfa (*Medicago sativa* L.)          *Agrobacterium* mediated\                              1 μg/g FW                                       \[[@B62-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Bluetongue virus-like particles                                Bluetongue virus                                                Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        70 mg/kg FW                                     \[[@B63-plants-09-00842]\]

  Narita 104 virus virus-like particles                          Narita 104 virus                                                Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        0.3 mg/g FW                                     \[[@B64-plants-09-00842]\]

  Glycoprotein (GP) of PRRSV                                     Porcine reproductive and respiratory syndrome virus (PRRSV)     *Arabidopsis thaliana*                  *Agrobacterium* mediated\                              2.74% of total soluble protein                  \[[@B65-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Matrix protein 2 ectodomain (M2e)                              Avian influenza (H5N1)                                          Duckweed (*Lemna minor*)                *Agrobacterium* mediated\                              90--970 mg/kg FW                                \[[@B66-plants-09-00842]\]
                                                                                                                                                                         (Stable expression/Nucleus)                                                                            

  Matrix protein 2 ectodomain (M2e)                              Avian influenza (H5N1)                                          Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated\                              125--205 mg/kg FW                               \[[@B67-plants-09-00842]\]
                                                                                                                                                                         (Transient expression)                                                                                 

  Consensus domain III of dengue virus E glycoprotein (cEDIII)   Dengue virus                                                    Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        5.2 mg/g FW                                     \[[@B68-plants-09-00842]\]

  Dengue envelop protein domain III (EDIII)                      Dengue virus                                                    Tobacco (*Nicotiana tabacum*)           Biolistic method (Stable expression/Chloroplast)       0.8--1.6% of total soluble protein              \[[@B69-plants-09-00842]\]

  PV3 VLPs                                                       Poliovirus (PV)                                                 Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        60 mg/kg FW                                     \[[@B28-plants-09-00842]\]

  *E. maxima* gametocyte antigen (Gam82)                         *Eimeria maxima*                                                Tobacco (*Nicotiana tabacum*)           *Agrobacterium* mediated (Transient expression)        20 mg/kg FW                                     \[[@B70-plants-09-00842]\]

  CHIKV E1 and E2                                                Chikungunya virus                                               Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        8--13 mg/kg of fresh leaf weight                \[[@B71-plants-09-00842]\]

  ZIKV envelope (E) protein                                      Zika virus (ZIKV)                                               Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        160 μg/g FW                                     \[[@B72-plants-09-00842]\]

  Porcine circovirus type 2 (PCV-2) capsid protein               Porcine circovirus type 2                                       Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated\                              6.5 mg/kg leaf wet weight                       \[[@B73-plants-09-00842]\]
                                                                                                                                                                         (Transient expression)                                                                                 

  HIV Env gp140                                                  Human immunodeficiency virus (HIV)                              Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        5--6 mg/kg FW                                   \[[@B74-plants-09-00842]\]

  H6 subtype haemagglutinin (HA)                                 Influenza A virus (H6N2)                                        Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated\                              95 mg/kg FW                                     \[[@B31-plants-09-00842]\]
                                                                                                                                                                         (Transient expression)                                                                                 

  **Antibodies**                                                                                                                                                                                                                                                                

  cT84.66                                                        Cancer (tumor marker)                                           Tobacco (*Nicotiana tabacum*)           *Agrobacterium* mediated (Transient expression)        1 mg/kg FW                                      \[[@B75-plants-09-00842]\]

  scFvT84.66                                                     Cancer (tumor marker)                                           Tobacco (*Nicotiana tabacum*)           *Agrobacterium* mediated (Transient expression)        5 mg/kg FW                                      \[[@B75-plants-09-00842]\]

  scFvT84.66                                                     Cancer (tumor marker)                                           Rice (*Oryza sativa*)                   Biolistic method (Stable expression/Nucleus)           3.8 μg/g FW                                     \[[@B76-plants-09-00842]\]

  scFvT84.66                                                     Cancer (tumor marker)                                           Cereal crops (wheat and rice)           Biolistic method (Stable expression/Nucleus)           30 μg/g FW                                      \[[@B77-plants-09-00842]\]

  BR55-2                                                         Human colorectal cancer                                         Tobacco (*Nicotiana tabacum*)           *Agrobacterium* mediated (Stable expression/Nucleus)   30 mg/kg FW                                     \[[@B78-plants-09-00842]\]

  2F5                                                            HIV                                                             Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Stable expression/Nucleus)   0.01% of total soluble protein                  \[[@B79-plants-09-00842]\]

  2G12                                                           HIV                                                             Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        0.3 g/kg FW                                     \[[@B80-plants-09-00842]\]

  2G12                                                           HIV                                                             Tobacco (*Nicotiana tabacum*)           *Agrobacterium* mediated (Stable expression/Nucleus)   8 mg/L culture medium                           \[[@B81-plants-09-00842]\]

  6D8                                                            Ebola virus                                                     Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        0.5 mg/g FW                                     \[[@B82-plants-09-00842]\]

  6D8                                                            Ebola virus                                                     Lettuce\                                *Agrobacterium* mediated (Transient expression)        0.23--0.27 mg/g FW                              \[[@B83-plants-09-00842]\]
                                                                                                                                 (*L. sativa*)                                                                                                                                  

  CO17-1AK                                                       Human colorectal cancer                                         Tobacco (*Nicotiana tabacum*)           *Agrobacterium* mediated (Stable expression/Nucleus)   0.25 mg/kg FW                                   \[[@B84-plants-09-00842]\]

  Palivizumab-N                                                  Respiratory syncytial virus                                     Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        180 mg/kg FW                                    \[[@B85-plants-09-00842]\]

  E559                                                           Rabies                                                          Tobacco (*Nicotiana tabacum*)           *Agrobacterium* mediated (Stable expression/Nucleus)   1.8 mg/kg FW (0.04% of total soluble protein)   \[[@B86-plants-09-00842]\]

  pE16                                                           West Nile virus                                                 Tobacco (*Nicotiana benthamiana* ∆XF)   *Agrobacterium* mediated (Transient expression)        0.74 mg/g FW                                    \[[@B87-plants-09-00842]\]

  pE16scFv-CH                                                    West Nile virus                                                 Tobacco (*Nicotiana benthamiana* ∆XF)   *Agrobacterium* mediated (Transient expression)        0.77 mg/g FW                                    \[[@B87-plants-09-00842]\]

  E60                                                            Dengue virus                                                    Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        120 μg/g FW                                     \[[@B88-plants-09-00842]\]

  2G12                                                           HIV                                                             Rice (*Oryza sativa*)                   Biolistic method (Stable expression/Nucleus)           46.4 μg/g dry seed weight                       \[[@B89-plants-09-00842]\]

  8B10 and 5F10                                                  Chikungunya virus                                               Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated\                              20--30 mg/kg FW                                 \[[@B71-plants-09-00842]\]
                                                                                                                                                                         (Transient expression)                                                                                 

  SO57                                                           Rabies virus                                                    Tobacco (*Nicotiana tabacum*)           *Agrobacterium* mediated (Transient expression)        0.014--0.019% of total soluble protein          \[[@B90-plants-09-00842]\]

  cD5                                                            Enterovirus 71                                                  Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        50 μg/g FW                                      \[[@B91-plants-09-00842]\]

  PD1                                                            Cancer                                                          Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        140 μg/g FW                                     \[[@B92-plants-09-00842]\]

  c2A10G6                                                        Zika virus                                                      Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        1.47 mg/g FW                                    \[[@B93-plants-09-00842]\]

  6D8                                                            Ebola                                                           Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        1.21 mg/g FW                                    \[[@B93-plants-09-00842]\]

  HSV8                                                           Herpes simplex virus                                            Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        1.42 mg/g FW                                    \[[@B93-plants-09-00842]\]

  CHKV mab                                                       Chikungunya virus                                               Tobacco (*Nicotiana benthamiana*)       *Agrobacterium* mediated (Transient expression)        100 μg/g FW                                     \[[@B94-plants-09-00842]\]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

plants-09-00842-t003_Table 3

###### 

Selected list of various non-pharmaceutical proteins produced in plants.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Recombinant Proteins                              Expression System                    Transformation Method                                          Expression Level                                         Reference
  ------------------------------------------------- ------------------------------------ -------------------------------------------------------------- -------------------------------------------------------- -----------------------------
  Human serum albumin                               Potato (*Solanum tuberosum*)         *Agrobacterium* mediated (Stable expression/Nucleus)           0.25 μg/mg (0.02% of total soluble protein)              \[[@B95-plants-09-00842]\]

  Erythropoietin                                    Tobacco (*Nicotiana tabacum*)        *Agrobacterium* mediated (Stable expression/Nucleus)           26 pg/mg total protein                                   \[[@B96-plants-09-00842]\]

  α1-antitrypsin                                    Rice (*Japonica* rice)               Biolistic method (Stable expression/Nucleus)                   4.6--5.7 mg/g dry cell                                   \[[@B97-plants-09-00842]\]

  Aprotinin                                         Corn                                 Biolistic method (Stable expression/Nucleus)                   0.069% of total extractable seed protein                 \[[@B98-plants-09-00842]\]

  Human-secreted alkaline phosphatase               Tobacco (*Nicotiana tabacum*)        *Agrobacterium* mediated (Stable expression/Nucleus)           1.1 μg/g FW (3% of total soluble protein)                \[[@B99-plants-09-00842]\]

  Collagen                                          Tobacco\                             *Agrobacterium* mediated (Stable expression/Nucleus)           0.03 g/kg powdered plants                                \[[@B100-plants-09-00842]\]
                                                    (*Nicotiana tabacum*)                                                                                                                                        

  Human somatotropin (hST)                          Tobacco                              Biolistic method\                                              \>7% of total soluble protein                            \[[@B101-plants-09-00842]\]
                                                                                         (Stable expression/Chloroplast)                                                                                         

  *Bacillus thuringiensis* (Bt) cry2Aa2             Tobacco                              Biolistic method\                                              5 mg/g FW (45.3--46.1% of total soluble protein)         \[[@B102-plants-09-00842]\]
                                                                                         (Stable expression/Chloroplast)                                                                                         

  Human serum albumin                               Tobacco (*Nicotiana tabacum*)        Biolistic method (Stable expression/Chloroplast)               11.1% of total protein                                   \[[@B103-plants-09-00842]\]

  Human epidermal growth factor (hEGF)              Tobacco (*Nicotiana tabacum*)        *Agrobacterium* mediated (Stable expression/Nucleus)           34.2 µg/g FW                                             \[[@B104-plants-09-00842]\]

  Human basic fibroblast growth factor (bFGF)       Soybean (*Glycine max*)              Cotyledonary node explant method (Stable expression/Nucleus)   2.3% of total soluble protein                            \[[@B105-plants-09-00842]\]

  Type I interferon (IFNα2b)                        Tobacco (*Nicotiana tabacum*)        Biolistic method (Stable expression/Chloroplast)               3 mg/g FW (20% of total soluble protein)                 \[[@B106-plants-09-00842]\]

  Human growth hormone (hGH)                        Rice (*Oryza sativa*)                Biolistic method (Stable expression/Nucleus)                   57 mg/L culture medium                                   \[[@B107-plants-09-00842]\]

  PlyGBS lysin                                      Tobacco\                             Biolistic method (Stable expression/Chloroplast)               \>70% of the total soluble protein                       \[[@B108-plants-09-00842]\]
                                                    (*Nicotiana tabacum*)                                                                                                                                        

  Human growth hormone (hGH)                        Tobacco BY-2 cells                   *Agrobacterium* mediated (Stable expression/Nucleus)           35 mg/L culture medium (2-4% of total soluble protein)   \[[@B109-plants-09-00842]\]

  Human basic fibroblast growth factor (bFGF)       Rice (*Oryza sativa*)                *Agrobacterium* mediated (Stable expression/Nucleus)           185.66 mg/kg                                             \[[@B110-plants-09-00842]\]

  Lumbrokinase                                      Sunflower (*Helianthus annuus* L.)   *Agrobacterium* mediated (Stable expression/Nucleus)           5.1 g/kg seeds                                           \[[@B111-plants-09-00842]\]

  Human acidic fibroblast growth factor 1 (FGF-1)   *Salvia miltiorrhiza*                *Agrobacterium* mediated (Stable expression/Nucleus)           272 ng/g FW                                              \[[@B112-plants-09-00842]\]

  Glucocerebrosidase (GCase)                        Tobacco (*Nicotiana benthamiana*)    *Agrobacterium* mediated (Stable expression/Nucleus)           68 μg/g FW (1.45% of total soluble protein)              \[[@B113-plants-09-00842]\]

  Human acid alpha glucosidase                      Tobacco\                             Biolistic method (Stable expression/Chloroplast)               6.38 μg/g FW                                             \[[@B114-plants-09-00842]\]
                                                    (*Nicotiana tabacum*)                                                                                                                                        

  Human basic fibroblast growth factor (bFGF)       Tobacco\                             Biolistic method (Stable expression/Chloroplast)               0.1% of total soluble protein                            \[[@B115-plants-09-00842]\]
                                                    (*Nicotiana tabacum*)                                                                                                                                        

  Endo-β-1,4-xylanase                               Tobacco\                             Biolistic method (Stable expression/Chloroplast)               35.7% of total soluble protein                           \[[@B116-plants-09-00842]\]
                                                    (*Nicotiana tabacum*)                                                                                                                                        

  β-Glucosidase                                     Tobacco\                             Biolistic method (Stable expression/Chloroplast)               \>75% of total soluble protein                           \[[@B116-plants-09-00842]\]
                                                    (*Nicotiana tabacum*)                                                                                                                                        

  Osteopontin (OPN)                                 Tobacco (*Nicotiana benthamiana*)    *Agrobacterium* mediated\                                      100 ng/g FW                                              \[[@B117-plants-09-00842]\]
                                                                                         (Transient expression)                                                                                                  

  Dentin matrix protein-1 (DMP1)                    Tobacco (*Nicotiana benthamiana*)    *Agrobacterium* mediated\                                      0.3 µg/g FW                                              \[[@B118-plants-09-00842]\]
                                                                                         (Transient expression)                                                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

4. Strategies Used for Recombinant Protein Production in Plants {#sec4-plants-09-00842}
===============================================================

The expression methods used for the recombinant protein production in plants can be either stable or transient expression. PMF relies on following approaches for the expression of vaccine candidates, i.e., stable nuclear transformation, stable chloroplast transformation, or transient expression, by using plant viral vectors and stable transformation of hydroponically grown plants in which recombinant proteins are recovered from the medium \[[@B119-plants-09-00842]\] ([Figure 1](#plants-09-00842-f001){ref-type="fig"}).

Stable nuclear transformation is the traditional strategy of genetic manipulation in plants for recombinant protein production. The transgene in the plant expression vector can be introduced into the in vitro grown plantlets either with *Agrobacterium tumefaciens*-mediated transformation or particle bombardment, and stable transgenic lines can be developed. The best transgenic line for protein production will be subsequently screened from the pool of transgenic lines. By this method, recombinant proteins can be produced in successive generations, as the transgene has been stably integrated into the plant genome. The model plants such as *Arabidopsis thaliana* and tobacco were more commonly used during the early stages of genetic transformation to develop stable transformants \[[@B79-plants-09-00842]\]. Stable transformation in plants requires substantial time and is a labor-intensive process, and the protein expression is insufficient to meet the industrial-level protein production. However, the antigen expression in stable transgenic line could be used for developing oral vaccines that could reduce the cost associated with protein purification \[[@B120-plants-09-00842],[@B121-plants-09-00842]\].

Alternatively, transient expression based on agroinfiltration or virus-based vectors have been developed to complement transgenic plants that offer rapid and high-level protein expression within a few days. The drawbacks and challenges associated with stable expression, such as insufficient protein expression, time, and consistency, have been overcome by the development of novel strategies involving deconstructed viral vector systems such as MagnICON^®^ technology, geminiviral, and pEAQ, which allows rapid accumulation of recombinant proteins in a short time \[[@B12-plants-09-00842]\]. Hence, it is considered as a suitable convenient platform, especially for the production of vaccine antigens or monoclonal antibodies against infectious diseases ([Figure 2](#plants-09-00842-f002){ref-type="fig"}). Gleba et al. (2007) summarized the application of plant viral vectors for the transient expression of heterologous proteins in plants \[[@B122-plants-09-00842]\]. Plant transient expression holds tremendous potential to produce rapid-response proteins, emergency vaccines, or biologics, which was impressively shown during the Ebola outbreak in 2014. Mapp Biopharmaceutical Inc., USA produced an experimental drug ZMapp, an anti-Ebola antibody cocktail of three chimeric monoclonal antibodies manufactured in tobacco plants (*Nicotiana benthamiana*) to treat humans during the recent Ebola outbreak \[[@B123-plants-09-00842]\]. During a pandemic situation, in order to cope with a rapidly spreading infectious disease, production methods should meet the demand for production targets of strategic vaccines to control the disease. One of the recent examples is the pandemic, corona virus disease (COVID-19). The virus has spread rapidly, and millions of people have been affected across 6 continents in few months, posing a constant threat to global health. This infection has created a massive demand for diagnostic reagents, vaccines, and therapeutic development. Given the speed advantages, and proven viability of the plant production platform, the transient expression system in particular could be employed to produce recombinant proteins at high levels to meet the sudden demand for production of viral antigens or antiviral proteins that could be used as research reagents, emergency vaccines (SARS-CoV-2 subunit and virus-like particle vaccines), or other biopharmaceuticals to fight against COVID-19 \[[@B25-plants-09-00842],[@B124-plants-09-00842]\]. The neutralizing monoclonal antibodies against SARS-CoV-2 could also be produced in plants with minimal investment, which could be used for passive immunotherapy \[[@B125-plants-09-00842]\]. Recently, Medicago (Quebec, Canada), Kentucky BioProcessing (Owensboro, KT, USA), and iBio (Bryan, TX, USA) joined the global race for developing potential plant-based vaccines for COVID-19 \[[@B126-plants-09-00842]\]. By using the transient expression platform, recombinant protein production in plants could be scaled up rapidly, and milligram quantities of proteins could be produced in a timeframe of less than 4 weeks after receiving the corresponding gene construct \[[@B5-plants-09-00842],[@B59-plants-09-00842],[@B127-plants-09-00842]\].

Alternately, chloroplast expression focuses on expressing the transgenes in chloroplast by the precise insertion of foreign DNA by homologous recombination into the chloroplast genome. Much progress has been made in chloroplast engineering in recent years. The transformation of the chloroplast genome has many advantages over nuclear transformation which includes higher protein production, lack of gene silencing and position effect, polycistronic mRNA expression, and prevention of transmission of foreign DNA through pollen by uniparental plastid gene inheritance (maternal inheritance) in crop plants \[[@B128-plants-09-00842],[@B129-plants-09-00842],[@B130-plants-09-00842],[@B131-plants-09-00842]\].

Similar to bacterial and mammalian cells, heterologous protein production can be achieved by using individual suspension of plant cells rather than whole plants. The cell suspension derived from undifferentiated callus grown in liquid medium can be scaled up in bioreactors for large-scale protein production under an aseptic environment. The first USDA-approved poultry vaccine and the first FDA-approved recombinant plant-produced pharmaceutical protein "Elelyso" were produced in tobacco and carrot cell suspension cultures, respectively, which proved the importance and competitiveness of plant suspension culture in high-value protein production in the biopharmaceutical industry \[[@B121-plants-09-00842],[@B132-plants-09-00842],[@B133-plants-09-00842],[@B134-plants-09-00842]\]. Hairy root cultures are also being explored as an alternative recombinant protein production system due to their ease in protein recovery and low costs. The recombinant proteins are secreted from the transgenic plant roots into the culture medium *viz.,* rhizosecretion; hence, this allows continuous protein production and recovery from the culture medium without the requirement of cell lysis during extraction. Moreover, recombinant proteins produced from root cultures attribute to the improved protein quality and quantity without complex downstream processing that could eventually reduce production costs as well \[[@B135-plants-09-00842]\]. A recent review on the applications of hairy root cultures for protein production has been extensively discussed by Gutierrez--Valdes et al. (2020) \[[@B136-plants-09-00842]\].

5. Perspectives {#sec5-plants-09-00842}
===============

Although plants are attractive with several unique advantages, they are unable to compete with the existing microbial and mammalian systems, as both are well established and characterized, especially in terms of GMP manufacturing and regulatory approval in an industrial setting. Even after many years of research, which has shown the proof-of-concept of expressing many therapeutic proteins in plants, the process of producing therapeutic proteins from the lab bench to commercialization is slow. Hence, in order to move forward, the commercial potential and economic sustainability of technology needs to be exploited by developing veterinary vaccines, non-pharmaceutical diagnostic, cosmetic products, and industrial enzymes in plants, as they have a low regulatory burden compared to therapeutic proteins \[[@B2-plants-09-00842],[@B9-plants-09-00842]\]. This technology can also be employed to reproduce rapid response vaccines or diagnostic reagents against emerging infections. For the past few years, extensive research has been carried out to combat the several emerging diseases including Zika, chikungunya, Nipah, SARS-CoV, MERS-CoV, and more recently SARS-CoV-2. Even though several efforts have been made for many years to develop effective vaccine candidates for many of those emerging and zoonotic diseases, still, there are no vaccine candidates or therapeutic measures available commercially. Even if a successful vaccine or drug developed against such diseases, it is unlikely that it would have a significant impact on developing and under-developed countries, due to the high cost associated with it, and scalability concern. In such a scenario, a plant-derived vaccine or diagnostic reagent would be a feasible approach to rapidly respond to the demand and need for recombinant proteins. However, harnessing the full potential of this plant molecular farming technology for cost-effective vaccines or drug development will be evident in the upcoming years.

6. Conclusions {#sec6-plants-09-00842}
==============

Plants have both economic and technical advantages over conventional expression systems for the production of pharmaceutical and non-pharmaceutical products. The different PMF technologies such as nuclear, chloroplast expression, viral transfection, and transient expression systems have their unique features, enabling them to address a production of diversified product "targets" with less production constraints in a short time. Many scientific and technical challenges associated with the plant platform were met in recent years. However, the regulatory burden associated with therapeutic protein production is a major barrier that hinders the widespread acceptance of the plant system. Considering the low costs and greater scalability of plant production systems, the commercialization of non-pharmaceutical proteins is straightforward and faster due to lower regulatory challenges. Hence, the universal acceptance of the technology will be strongly influenced by the regulatory framework and restrictions applied to plant-derived products worldwide. The demand for industrially or pharmaceutically useful recombinant proteins, together with demonstrated production capability and economic feasibility of the plant system, suggests a bright future for the plant-made biologics.
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